MENU
Showcases Stock ranks Forex

Adamas Pharma (ADMS)
8.22  0 (0%) 12-31 19:00
Open: 8.24 Pre. Close: 8.22
High: 8.25 Low: 8.18
Volume: 3,151,400 Market Cap: 0(M)
Stock Technical Analysis
Overall:     
Target: Six months: 9.64
One year: 11.25
Support: Support1: 8.21
Support2: 8.18
Resistance: Resistance1: 8.25
Resistance2: 9.64
Pivot: 8.22
Moving Averages: MA(5): 8.22
MA(20): 8.22
MA(100): 7.43
MA(250): 6.05
MACD: MACD(12,26): 0.01
Signal(12,26,9): 0.02
%K %D: %K(14,3): 57.14
%D(3): 57.14
RSI: RSI(14): 73.53
52-Week: High: 9.15
Low: 4.02
Change(%): 51.7
Average Vol(K): 3-Month: 2571
10-Days: 3151
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 8.269 - 8.31 8.31 - 8.343
Low: 8.065 - 8.122 8.122 - 8.167
Close: 8.142 - 8.226 8.226 - 8.295
Price, MAs and Bollinger Bands
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.

ADMS has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to Adamas Pharma's normal range. The bands have been in this narrow range for 63 bars. This is a sign that the market may be about to initiate a new trend.
Company profile
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
Stock chart
Stock News
Wed, 24 Nov 2021
Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals - GlobeNewswire

Tue, 26 Oct 2021
Adamas Pharmaceuticals Stock: An Acceptable Buyout At The Perfect Time (NASDAQ:ADMS) - Seeking Alpha

Tue, 12 Oct 2021
Supernus expands CNS portfolio with buy of Adamas Pharma - The Pharma Letter

Mon, 11 Oct 2021
Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio - GlobeNewswire

Mon, 11 Oct 2021
Flexion and Adamas Are Being Acquired. Both Stocks Are Soaring. - Barron's

Mon, 01 Mar 2021
Adamas Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters ... - Business Wire

Financial Analysis
Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Drug Manufacturers - Specialty & Generic
Shares Out. (M) 45.69
Shares Float (M) 30.87
% Held by Insiders 1.75
% Held by Institutions 80.34
Shares Short (K) 1600
Shares Short Prior Month (K) 2510
Stock Financials
EPS -1.600
Book Value (p.s.) -0.090
Profit Margin -66.82
Operating Margin -45.13
Return on Assets (ttm) -16.4
Return on Equity (ttm)
Qtrly Rev. Growth 16.9
Gross Profit (p.s.) 1.585
Sales Per Share 1.805
EBITDA (p.s.) -0.801
Qtrly Earnings Growth
Operating Cash Flow (M) -51.42
Levered Free Cash Flow (M) -28.95
Stock Valuation
PE Ratio -5.14
PEG Ratio
Price to Book value -91.33
Price to Sales 4.55
Price to Cash Flow
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android